INCYTE WKN: 896133 ISIN: US45337C1027 Kürzel: INCY Forum: Aktien Thema: Hauptdiskussion

https://www.businesswire.com/news/home/20200918005082/en/Incyte-Announces-Encouraging-Results-From-Phase-2-Trial-of-Retifanlimab-INCMGA0012-in-Patients-With-Previously-Treated-Advanced-Squamous-Cell-Carcinoma-of-the-Anal-Canal Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal

Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time https://www.marketwatch.com/story/shares-of-lilly-and-incyte-gain-after-late-stage-study-finds-their-arthritis-drug-can-help-reduce-covid-19-recovery-time-2020-09-14

Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM https://www.businesswire.com/news/home/20200902005825/en/Incyte-Announces-Pivotal-GEOMETRY-mono-1-Study-Results

Wird eher Morphosys betreffen, denke ich.

Müsste doch steigen oder??

MorphoSys' tafasitamab added to U.S. treatment guidelines for type of blood cancer https://seekingalpha.com/news/3606850-morphosys-tafasitamab-added-to-u-s-treatment-guidelines-for-type-of-blood-cancer MorphoSys AG (NASDAQ:MOR) and collaborator/licensee Incyte (NASDAQ:INCY) announce that Monjuvi (tafasitamab-cxix) has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-cell lymphomas.

https://seekingalpha.com/news/3599714-incyte-eps-beats-0_37-beats-on-revenue

https://www.businesswire.com/news/home/20200723005089/en/Incyte-Announces-REACH3-Trial-Ruxolitinib-Jakafi%C2%AE-Patients Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints

https://investor.incyte.com/incyte-news/press-releases Incyte gibt die Zulassung von Tabrecta ™ (Capmatinib) in Japan zur Behandlung von Patienten mit fortgeschrittenem nicht-kleinzelligem Lungenkrebs mit METex14 bekannt

So langsam wird es wieder etwas attraktiver hier einzusteigen bzw. Nachzulegen.

https://finance.yahoo.com/news/incyte-reports-2020-first-quarter-110000371.html?theme=2&_v=1&color=1&hl=en&sp=1

Sieht gut aus

https://www.deraktionaer.de/artikel/pharma-biotech/virica-index-es-geht-schlag-auf-schlag-bei-incyte-regeneron-und-co-die-rekordjagd-geht-weiter-20200015.html

👍🍀

Und noch nen fda approval hinterher

Hier ist etwas, dass Sie vielleicht interessieren könnte: https://www.wallstreet-online.de/nachricht/12417646-fda-approves-incyte-s-pemazyre-pemigatinib-as-first-targeted-treatment-for-adults-with-previously-treated-unresectable-locally-advanced-or-metastatic-cholangiocarcinoma